Gene · 862
NIH grants2,053
NIH grants whose papers are about the gene, through NIH's grant-paper links.
201 to 220 of 2,053
Download this page as JSON| Grant | Title | RUNX1T1 papers | Newest fiscal year |
|---|---|---|---|
| R00CA252602 | Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemia | 1 | 2025 |
| R01AI061061 | Molecular characterization of the role for metabolites in immune cell differentiation | 1 | 2025 |
| R01AI118891 | Viral modulation of epitranscriptomic mechanisms | 1 | 2025 |
| R01AI125416 | Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | 1 | 2025 |
| R01AI128775 | Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data | 1 | 2025 |
| R01AI153442 | An experimentally-refined, dynamic gene regulatory network model of T-cell memory | 1 | 2025 |
| R01AI155662 | Harnessing the anti-inflammatory activity of extracellular sialylation of IgG. | 1 | 2025 |
| R01AI168004 | Role of Class IIa HDACs HDAC4 and HDAC7 in Pathogenic Th17 Cell Development and Colitis | 1 | 2025 |
| R01CA069202 | Structure/Function of Protein Tyrosine Phosphatases | 1 | 2025 |
| R01CA096512 | Cell model for KSHV infection and genetic manipulation | 1 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA102184 | Functional Analysis of p53 Polymorphic Variants | 1 | 2025 |
| R01CA124332 | Regulation of KSHV replication by N6-methyladenosine (m6A) | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA152108 | Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML) | 1 | 2025 |
| R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 1 | 2025 |
| R01CA173852 | Role of p21 activated kinase in Leukemogenesis | 1 | 2025 |
| R01CA180986 | E-FABP mediates n-3 fatty acid-induced tumor prevention through epigenetic control of immune cell differentiation and function | 1 | 2025 |
| R01CA186702 | Mechanisms of epitranscriptomic regulation in cancer | 1 | 2025 |
| R01CA188228 | Evolution of gliomas during treatment and resistance | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/grants?page=11